Cereno Scientific strengthens its organization and engages a Chief Medical Officer before the start of a phase II study with CS1
Cereno Scientific announces today that the company engages Björn Dahlöf as Chief Medical Officer (CMO). Dahlöf, who is a Board member and principal owner, has extensive experience in cardiovascular research, pharmacology, drug development and clinical testing in all phases, and has lectured internationally in these fields.“I have had the privilege of working with Björn Dahlöf for four years, and it is gratifying for us to link him more closely with Cereno’s development work. Björn is a global key opinion leader, and his extensive experience in drug development and international network of